• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经典型霍奇金淋巴瘤中的信号通路与免疫逃逸机制

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.

作者信息

Liu W Robert, Shipp Margaret A

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

出版信息

Blood. 2017 Nov 23;130(21):2265-2270. doi: 10.1182/blood-2017-06-781989.

DOI:10.1182/blood-2017-06-781989
PMID:29167175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5701523/
Abstract

Classical Hodgkin lymphoma (cHL) is an unusual B-cell-derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an extensive but ineffective inflammatory/immune cell infiltrate. This striking feature suggests that malignant HRS cells escape immunosurveillance and interact with immune cells in the cancer microenvironment for survival and growth. We previously found that cHLs have a genetic basis for immune evasion: near-uniform copy number alterations of chromosome 9p24.1 and the associated PD-1 ligand loci, CD274/PD-L1 and PDCD1LG2/PD-L2, and copy number-dependent increased expression of these ligands. HRS cells expressing PD-1 ligands are thought to engage PD-1 receptor-positive immune effectors in the tumor microenvironment and induce PD-1 signaling and associated immune evasion. The genetic bases of enhanced PD-1 signaling in cHL make these tumors uniquely sensitive to PD-1 blockade.

摘要

经典型霍奇金淋巴瘤(cHL)是一种罕见的B细胞来源的恶性肿瘤,其中罕见的恶性霍奇金和里德-斯腾伯格(HRS)细胞被广泛但无效的炎症/免疫细胞浸润所包围。这一显著特征表明,恶性HRS细胞逃避免疫监视,并在癌症微环境中与免疫细胞相互作用以实现生存和生长。我们之前发现,cHL具有免疫逃逸的遗传基础:9号染色体p24.1区域以及相关的PD-1配体基因座CD274/PD-L1和PDCD1LG2/PD-L2存在近乎一致的拷贝数改变,且这些配体的表达随拷贝数增加。表达PD-1配体的HRS细胞被认为会与肿瘤微环境中PD-1受体阳性的免疫效应细胞相互作用,诱导PD-1信号传导及相关的免疫逃逸。cHL中增强的PD-1信号传导的遗传基础使得这些肿瘤对PD-1阻断具有独特的敏感性。

相似文献

1
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.经典型霍奇金淋巴瘤中的信号通路与免疫逃逸机制
Blood. 2017 Nov 23;130(21):2265-2270. doi: 10.1182/blood-2017-06-781989.
2
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.经典型霍奇金淋巴瘤中的信号通路和免疫逃逸机制。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):310-316. doi: 10.1182/asheducation-2017.1.310.
3
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.程序性死亡配体1(PD-L1)和程序性死亡配体2(PD-L2)基因改变可定义经典型霍奇金淋巴瘤并预测预后。
J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11.
4
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.拓扑分析揭示了霍奇金淋巴瘤中里德-施特恩伯格细胞的一种与程序性死亡配体1相关的微环境生态位。
Blood. 2017 Nov 30;130(22):2420-2430. doi: 10.1182/blood-2017-03-770719. Epub 2017 Sep 11.
5
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.主要组织相容性复合体 II 类和程序性死亡配体 1 表达预测经典霍奇金淋巴瘤接受程序性死亡 1 阻断后的结局。
J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.
6
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.β2M/MHC I类分子表达降低的经典型霍奇金淋巴瘤与不良预后相关,与9p24.1状态无关。
Cancer Immunol Res. 2016 Nov;4(11):910-916. doi: 10.1158/2326-6066.CIR-16-0201. Epub 2016 Oct 13.
7
Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment.霍奇金淋巴瘤的液滴式细胞术分析显示富含 CD4 调节性 T 细胞和耗竭的 T 效应细胞的微环境。
Blood. 2018 Aug 23;132(8):825-836. doi: 10.1182/blood-2018-04-843714. Epub 2018 Jun 7.
8
Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.免疫组织化学评估 PD-L1 的诊断效用:抗 PD-L1 抗体(SP142)在具有肿瘤和非恶性霍奇金-里德-斯特恩伯格(HRS)样细胞的淋巴增生性疾病中的初步分析。
Histopathology. 2018 Jun;72(7):1156-1163. doi: 10.1111/his.13475. Epub 2018 Mar 9.
9
The biology of classical Hodgkin lymphoma.经典型霍奇金淋巴瘤的生物学特性。
Semin Hematol. 2024 Aug;61(4):212-220. doi: 10.1053/j.seminhematol.2024.05.001. Epub 2024 May 8.
10
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.对分选的霍奇金 Reed-Sternberg 细胞进行基因组分析揭示了免疫逃逸的互补机制。
Blood Adv. 2019 Dec 10;3(23):4065-4080. doi: 10.1182/bloodadvances.2019001012.

引用本文的文献

1
Immune Deficiency/Dysregulation-Associated EBV-Positive Classic Hodgkin Lymphoma.免疫缺陷/失调相关的EB病毒阳性经典型霍奇金淋巴瘤
Cancers (Basel). 2025 Apr 25;17(9):1433. doi: 10.3390/cancers17091433.
2
Viral oncogenesis in cancer: from mechanisms to therapeutics.癌症中的病毒致癌作用:从机制到治疗
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
3
Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics.经典型霍奇金淋巴瘤患者游离DNA的分子谱分析确定了潜在的预后聚类,并与疾病动态变化相关。
Ann Hematol. 2025 Mar;104(3):1789-1800. doi: 10.1007/s00277-025-06328-8. Epub 2025 Apr 8.
4
PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma.PRMT3通过激活肝细胞癌中PDHK1调节的糖酵解驱动PD-L1介导的免疫逃逸。
Cell Death Dis. 2025 Mar 6;16(1):158. doi: 10.1038/s41419-025-07482-7.
5
The Abundance of FOXP3, FOXP3/CD4 and CD8 Cells in the Microenvironment of Nodular Sclerosis and Mixed Cellularity Subtypes Is Associated with the Epstein-Barr Virus Status of Classic Hodgkin Lymphoma.结节硬化型和混合细胞型经典霍奇金淋巴瘤微环境中FOXP3、FOXP3/CD4及CD8细胞的丰度与爱泼斯坦-巴尔病毒状态相关。
Biomedicines. 2024 Jul 27;12(8):1680. doi: 10.3390/biomedicines12081680.
6
Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects.晚期及复发/难治性霍奇金淋巴瘤中的免疫检查点抑制剂:当前应用与未来前景
Front Oncol. 2024 Apr 18;14:1397053. doi: 10.3389/fonc.2024.1397053. eCollection 2024.
7
Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.解析经典型霍奇金淋巴瘤的免疫微环境:对预后和治疗的意义
Biology (Basel). 2023 Jun 15;12(6):862. doi: 10.3390/biology12060862.
8
Genetic lesions and targeted therapy in Hodgkin lymphoma.霍奇金淋巴瘤中的基因损伤与靶向治疗
Ther Adv Hematol. 2023 Jan 12;14:20406207221149245. doi: 10.1177/20406207221149245. eCollection 2023.
9
The role of immunohistochemistry in the assessment of classical Hodgkin lymphoma microenvironment.免疫组织化学在经典型霍奇金淋巴瘤微环境评估中的作用
Int J Clin Exp Pathol. 2022 Oct 15;15(10):412-424. eCollection 2022.
10
Longitudinal Body Composition Changes Detected by [F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma.化疗期间及化疗后通过[F]FDG PET/CT检测到的老年霍奇金淋巴瘤患者身体成分的纵向变化及其预后作用
Cancers (Basel). 2022 Oct 20;14(20):5147. doi: 10.3390/cancers14205147.

本文引用的文献

1
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.拓扑分析揭示了霍奇金淋巴瘤中里德-施特恩伯格细胞的一种与程序性死亡配体1相关的微环境生态位。
Blood. 2017 Nov 30;130(22):2420-2430. doi: 10.1182/blood-2017-03-770719. Epub 2017 Sep 11.
2
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.肿瘤相关巨噬细胞的PD-1表达抑制吞噬作用和肿瘤免疫。
Nature. 2017 May 25;545(7655):495-499. doi: 10.1038/nature22396. Epub 2017 May 17.
3
HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?B细胞淋巴瘤中依赖人类白细胞抗原的免疫逃逸机制:对免疫检查点抑制剂治疗的意义?
Oncoimmunology. 2017 Mar 3;6(4):e1295202. doi: 10.1080/2162402X.2017.1295202. eCollection 2017.
4
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.帕博利珠单抗在复发/难治性原发性纵隔大B细胞淋巴瘤患者中的安全性和耐受性。
Blood. 2017 Jul 20;130(3):267-270. doi: 10.1182/blood-2016-12-758383. Epub 2017 May 10.
5
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.帕博利珠单抗治疗复发/难治性经典型霍奇金淋巴瘤的疗效和安全性II期研究。
J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25.
6
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.纳武单抗进行程序性死亡受体1阻断治疗复发/难治性原发性中枢神经系统淋巴瘤和睾丸淋巴瘤。
Blood. 2017 Jun 8;129(23):3071-3073. doi: 10.1182/blood-2017-01-764209. Epub 2017 Mar 29.
7
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.通过靶向PD-1疗法挽救耗竭的CD8 T细胞是依赖CD28的。
Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.
8
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.T细胞共刺激受体CD28是PD-1介导抑制作用的主要靶点。
Science. 2017 Mar 31;355(6332):1428-1433. doi: 10.1126/science.aaf1292. Epub 2017 Mar 9.
9
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.程序性死亡蛋白1(PD-1)检查点通路的分子与生化方面
N Engl J Med. 2016 Nov 3;375(18):1767-1778. doi: 10.1056/NEJMra1514296.
10
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.双重PI3K/ERK抑制通过下调IER3诱导霍奇金淋巴瘤细胞坏死性凋亡。
Sci Rep. 2016 Oct 21;6:35745. doi: 10.1038/srep35745.